US Physical Therapy Inc

USPH is in a Stage 2 advancing phase within a confirmed uptrend, marked by higher highs and higher lows above rising EMAs. Price is extended above the 9/20 EMA regime and approaching the 200 DMA with extreme overbought readings, suggesting an imminent pullback. We will stalk for a corrective retracement into the 9/20 EMA and 50 DMA support zones before scaling exposure, consistent with a momentum‐oriented execution style.

• ↑Q1 revenue $198M, +7.9% YoY, driven by hospital partnerships expansion.
• ↑Average visits per clinic jumped to 32.7/day, net promoter score 93.5.
• ↓Shares trade at 142.6x P/E, reflecting high valuation vs peers.